 New York, NY, and Tel Aviv, ISRAEL, Oct. 04, 2021 GLOBE NEWSWIRE -- via NewMediaWire -- Todos Medical, Ltd. Todos Medical OTCQB: TOMDF, a comprehensive medical diagnostics and related solutions company, today provided an update on its COVID-19 oral antiviral 3CL protease Main Protease, or Mpro inhibitor Tollovir clinical development program currently enrolling a Phase 2 clinical trial in hospitalized patients at Shaare Zedek Medical Center in Jerusalem, Israel. In light of the Data Safety Monitoring Board DSMB overseeing Mercks trial in consultation with the US Food Drug Administration FDA stopping enrollment after an interim analysis of 775 patient revealed a 50 reduction in the risk of hospitalization and death in unvaccinated outpatient COVID-19 patients recruited into Mercks Phase 3 clinical trial within 5 days of symptom onset, Todos has now begun a thorough re-evaluation of outpatient trial designs to provide the fastest path to bring Tollovir to market in the outpatient setting given the now significantly lower than expected patient enrollment threshold required to demonstrate efficacy. 